Close Menu

NEW YORK (GenomeWeb) – HIV-1 can acquire resistance to editing by CRISPR/Cas9 in CD4+ SupT1 cell lines, according to the results of a new study, and in fact, it's the mechanics of the Cas9 enzyme that allows the virus to acquire benign mutations that ultimately render gene editing useless.

Led by McGill University Professor Chen Liang, the study's authors showed that while CRISPR/Cas9 can efficiently target and excise proviral DNA integrated in the host genome, gene editing can lead to mutations that allow the virus to persist in some cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.